Evidence map›Paper›PMID 36267098›Full record

ArticleThe World Allergy Organization journal2022

Prospective analysis of clinical evolution in chronic urticaria: Persistence, remission, recurrence, and pruritus alone.

Jorge Sánchez, Leidy Álvarez, Ricardo Cardona

Abstract read
In one paragraph

Article in The World Allergy Organization journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Evaluation of the clinical utility of medical tests in chronic urticaria.The journal of allergy and clinical immunology. Global · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jorge SánchezGroup of Clinical and experimental Allergy, Hospital Alma Mater de Antioquia, University of Antioquia, Colombia.
Leidy ÁlvarezAcademic Group of Clinical Epidemiology (GRAEPIC), University of Antioquia, Colombia.
Ricardo CardonaGroup of Clinical and experimental Allergy, Hospital Alma Mater de Antioquia, University of Antioquia, Colombia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Population and study's methodology heterogenicity became clinical evolution of chronic spontaneous urticaria (CSU) highly variable. Objective: In a prospective cohort, we evaluated the different pathways of clinical evolution of CSU and identified possible risk factors. Methods: A total of 685 CSU patients (>12 years) were prospectively followed over 5 years. Diagnosis and follow-up of urticaria were based on medical evaluation and photographic records. Remission was defined as at least 6 months without symptoms (hives, angioedema, or pruritus) and medication. The follow-up included at least 2 visits per year, with photographic registration and clinical evaluation. Predefined clinical and paraclinical variables were included in the regression analyses. Results: We identified four clinical evolution pathways; The cumulative prevalence of remission at 5 years was 59.1%, recurrence was 17.1%, persistence was 11.6%, and chronic pruritus without hives or angioedema was 12.2%. The probability of persistence increased with hypothyroidism diagnosis (HR 0.425, 95% CI 0.290-0.621) and each point in the UAS7 (HR 0.931 95% CI 0.918-0.945). Conclusion: Chronic urticaria has different evolutions. Disease activity and hypothyroidism predict persistence and remission. Recurrence and chronic pruritus phenotypes require further study to evaluate their causality and prognosis.

Indexed as

Chronic pruritusPersistenceRecurrenceRemissionUrticaria

Identifiers

PMID36267098
PMCPMC9554810

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.